News
Director Renee Tannenbaum sells 2,000 shares of ANI Pharmaceuticals Inc (ANIP)
On May 16, 2024, Renée TannenbaumDirector of ANI Pharmaceuticals Inc (NASDAQ:ANIP), carried out a sale of 2,000 shares of the company. The transaction was registered on the same day through a SEC Filing. The shares were sold at a price of US$63.87 each, totaling US$127,740.
ANI Pharmaceuticals Inc is engaged in the development, manufacturing and marketing of branded and generic pharmaceutical products. The company’s products are focused on several therapeutic areas, including hormones, anti-cancer, respiratory and dermatological.
Last year the insider sold a total of 2,000 shares and made no purchases. The broader trend of insider transactions at ANI Pharmaceuticals Inc shows a pattern of 50 insider sales and no insider purchases over the same period.
Director Renee Tannenbaum sells 2,000 shares of ANI Pharmaceuticals Inc (ANIP)
As far as valuation goes, ANI Pharmaceuticals Inc shares were trading at $63.87 on the day of the sale, giving the company a market value of approximately US$1.29 billion. O price-earnings ratio of the company is 38.88, above the industry median of 24.38.
The stock FG Value is estimated at $58.72, leading to a GF price-to-value ratio of 1.09, indicating the stock is reasonably valued.
Director Renee Tannenbaum sells 2,000 shares of ANI Pharmaceuticals Inc (ANIP)
GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates provided by Morningstar analysts.
This insider selling may interest investors to monitor internal behavior as an indicator of potential stock performance, particularly in the context of company valuation and market trends.
This article, generated by GuruFocus, is designed to provide general insights and is not personalized financial advice. Our comments are based on historical data and analyst projections, using an unbiased methodology, and are not intended to serve as specific investment advice. It does not make a recommendation to purchase or dispose of any shares and does not consider individual investment objectives or financial circumstances. Our goal is to provide data-driven, long-term fundamental analysis. Please be aware that our analysis may not incorporate the latest price-sensitive company announcements or qualitative information. GuruFocus does not hold any position in the stocks mentioned here.
This article first appeared in GuruFocus.